US 12,440,529 B2
Topical Croton lechleri compositions and their use in the treatment of a bacterial colonization or primary or secondary bacterial infection of an underlying skin disorder
Gary Michael Pekoe, Cincinnati, OH (US); Jazmyne Kristyne Mink, Cincinnati, OH (US); Steven Aaron Pentelnik, Cincinnati, OH (US); and Neal G. Koller, Annapolis, MD (US)
Assigned to Alphyn Biologics, Inc., Annapolis, MD (US)
Filed by ALPHYN BIOLOGICS, INC., Annapolis, MD (US)
Filed on Sep. 22, 2021, as Appl. No. 17/482,369.
Claims priority of provisional application 63/081,657, filed on Sep. 22, 2020.
Claims priority of provisional application 63/081,665, filed on Sep. 22, 2020.
Prior Publication US 2022/0110992 A1, Apr. 14, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 36/47 (2006.01); A61K 31/343 (2006.01); A61K 31/352 (2006.01); A61K 31/353 (2006.01); A61P 31/04 (2006.01)
CPC A61K 36/47 (2013.01) [A61K 31/343 (2013.01); A61K 31/352 (2013.01); A61K 31/353 (2013.01); A61P 31/04 (2018.01)] 21 Claims
 
1. A method of treating atopic dermatitis in a subject in need thereof comprising topically administering to affected areas of the subject a pharmaceutical composition containing a therapeutically effective amount of filtered latex of Croton lechleri, wherein the therapeutically effect amount of filtered latex of Croton lechleri is about 40 wt %, wherein the atopic dermatitis is treated, and wherein the outcome is selected from a decrease in IGA score by at least 1 point, a decrease in EASI by at least 20%, an improvement in Peak Pruritus NRS score, and a combination thereof.